While 88.1% of patients completed one cycle, patient adherence beyond the fourth cycle was relatively low.

The results from the Phase III trial found the LDL-C treatment to be well tolerated with a reduction in low-density lipoprotein cholesterol.

The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM) - comprising the US, the five major European markets (France, Germany, Italy, Spain, and the UK), Japan, ...

The EMA has validated Chiesi Global Rare Diseases and Protalix’s submission to update the dosing regimen of pegunigalsidase alfa.

An improved price discount and new evidence from Santhera has changed NICE’s tune following a recommendation shun earlier this year.

The biopharmaceutical industry is being called to take its sustainability efforts to the next level. A new report sheds light ...

Seres Therapeutics has received US FDA breakthrough therapy designation for its SER-155, aimed at decreasing BSIs.